In an incredibly sunny London, our CTO Giuseppe Roscilli had the pleasure to present our innovative approaches for generating and producing monoclonal antibodies at the Antibody and Engineering Therapeutics Congress.

Utilizing #technologies like DNA-EGT, we efficiently produce high-quality antibodies, surpassing the limitations of conventional methods.

Our high-throughput techniques for screening antibody phenotypes and antigen specificity from primary B cells provide a cost-effective and efficient platform for identifying antigen-specific antibodies from human and mouse B cells.

These advancements are combined with high-troughput antibody production and purification, enhancing antibody research and therapeutic applications.

Our comprehensive approach offers tailored, high-quality antibodies and efficient solutions for diverse #health challenges, underscoring the critical role of antibodies in #science and #medicine.

Follow our page Takis to stay updated on our latest #biotech #research!